According to Blueprint Medicines 's latest financial reports the company's current revenue (TTM ) is S$0.59 Billion. In 2023 the company made a revenue of S$0.32 Billion an increase over the revenue in the year 2022 that were of S$0.27 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2024 (TTM) | S$0.57 B | 74.97% |
2023 | S$0.32 B | 20.41% |
2022 | S$0.27 B | 12.36% |
2021 | S$0.24 B | -76.82% |
2020 | S$1.05 B | 1071.03% |
2019 | S$89.67 M | 47.43% |
2018 | S$60.82 M | 112.24% |
2017 | S$28.65 M | -28.7% |
2016 | S$40.19 M | 149.26% |
2015 | S$16.12 M |